NXTC
XNAS
Market cap29mUSD
Nov 20, Last price
6.45USD
1D
-4.87%
1Q
2.54%
IPO
-97.24%
Name
NextCure Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
NextCure, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative immunotherapies. Its core mission is to combat cancer and various other immune-related conditions by reactivating normal immune system function. The company's leading investigational compound, NC318, is currently in Phase II clinical trials, focusing on the treatment of advanced or metastatic solid tumors. Additionally, NextCure is progressing NC410 through Phase I studies; this novel immunomedicine is engineered to counteract immune suppression mediated by Leukocyte-Associated Immunoglobulin-like Receptor 1 (LAIR-1). Another asset, NC762, is an immunotherapeutic designed to target the human B7 homolog 4 protein (B7-H4). Furthermore, NC525, a distinct LAIR-1 antibody, is undergoing preclinical assessment for its potential efficacy against acute myeloid leukemia, specifically targeting blast cells and leukemic stem cells. Beyond these specific pipeline candidates, NextCure's broader research and development efforts encompass the preclinical evaluation of other promising immunomodulatory antibodies and molecules. The company operates under a licensing agreement with Yale University. NextCure, Inc. was established in 2015 and maintains its corporate headquarters in Beltsville, Maryland.
Key people
David Kabakoff
Independent Chairman of the Board · since 2015
Steven Cobourn
Chief Financial Officer · since 2018
Timothy Mayer
Chief Operating Officer · since 2019
Sourav Kundu
Senior Vice President - Development and Manufacturing · since 2021
Kevin Shaw
Senior Vice President, General Counsel · since 2023
Udayan Guha
Chief Medical Officer · since 2025
President, Chief Executive Officer, Director · since 2015
Independent Director · since 2021
Independent Director · since 2021
John Houston
Independent Director · since 2020
Independent Director · since 2015
Independent Director · since 2019
Legal address
C/O THE CORPORATION TRUST COMPANY
CORPORATION TRUST CENTER 1209 ORANGE ST
WILMINGTON, DE 19801
US
CORPORATION TRUST CENTER 1209 ORANGE ST
WILMINGTON, DE 19801
US
Headquarters
9000 Virginia Manor Road
Suite 200
Beltsville, MD 20705
US
Suite 200
Beltsville, MD 20705
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||